ALLMedicine™ Acromegaly Center

Jan 21st, 2021 - Acromegaly is characterized by increased serum concentrations of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Although animal studies have demonstrated a relationship between these hormones and cancer risk, the results of human st...

Jan 20th, 2021 - To evaluate current real-life experience with medical treatment for active acromegaly in a large cohort. Data on demographic parameters, blood tests, imaging studies, and treatments were extracted from the medical records. The cohort included 87 p...

Jan 15th, 2021 - This study aimed to evaluate the retinal blood vessel parameters and the foveal avascular zone (FAZ) area using optical coherence tomography angiography (OCTA) in patients with acromegaly in comparison with healthy controls. A total of 45 patients...

Jan 14th, 2021 - Described for the first time in 1985, Carney complex (CNC) is a rare dominantly inherited multiple neoplasia syndrome with almost full penetrance, and characterized by both endocrine - primary pigmented nodular adrenocortical disease with Cushing'...

Jan 12th, 2021 - Somatostatin analogs (SSAs) are used to treat neuroendocrine tumors (NETs) and acromegaly. Two first-generation SSAs, octreotide long-acting release (OCT LAR) and lanreotide autogel/depot (LAN), are available. A systematic literature review (SLR) ...

Feb 25th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Dec 31st, 2015 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Oct 30th, 2014 - The aim was to formulate clinical practice guidelines for acromegaly. The Task Force included a chair selected by the Endocrine Society Clinical Guidelines Subcommittee (CGS), five experts in the field, and a methodologist. The authors received no...

Feb 25th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

Aug 23rd, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...

Jan 21st, 2021 - Acromegaly is characterized by increased serum concentrations of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Although animal studies have demonstrated a relationship between these hormones and cancer risk, the results of human st...

Jan 20th, 2021 - To evaluate current real-life experience with medical treatment for active acromegaly in a large cohort. Data on demographic parameters, blood tests, imaging studies, and treatments were extracted from the medical records. The cohort included 87 p...

Jan 15th, 2021 - This study aimed to evaluate the retinal blood vessel parameters and the foveal avascular zone (FAZ) area using optical coherence tomography angiography (OCTA) in patients with acromegaly in comparison with healthy controls. A total of 45 patients...

Jan 14th, 2021 - Described for the first time in 1985, Carney complex (CNC) is a rare dominantly inherited multiple neoplasia syndrome with almost full penetrance, and characterized by both endocrine - primary pigmented nodular adrenocortical disease with Cushing'...

Jan 12th, 2021 - Somatostatin analogs (SSAs) are used to treat neuroendocrine tumors (NETs) and acromegaly. Two first-generation SSAs, octreotide long-acting release (OCT LAR) and lanreotide autogel/depot (LAN), are available. A systematic literature review (SLR) ...

Sep 15th, 2020 - Answer 5/5 Which of the following is accurate regarding treatment of acromegaly? Your peers chose: Pharmacologic therapy is the first-line treatment for acromegaly 0% Radiation therapy is routinely indicated for most patients with acromegaly 0% Fo...

Sep 15th, 2020 - Causes of excess IGF-I action can be divided into the following three categories: Release of primary GH excess from the pituitary Increased GHRH secretion or hypothalamic dysregulation Hypothetically, the excessive production of IGF-binding protei...

Sep 15th, 2020 - Gigantism refers to abnormally high linear growth due to excessive action of insulin-like growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the gr...

Sep 15th, 2020 - Gigantism is extremely rare, with approximately 100 reported cases to date. Acromegaly is more common than gigantism, with an incidence of 3-4 cases per million people per year and a prevalence of 60 cases per million population. A claims-based an...

Jun 28th, 2020 - The US Food and Drug Administration (FDA) has approved oral octreotide (Mycapssa, Chiasma) delayed-release capsules for the long-term maintenance treatment of patients with acromegaly who previously responded to and tolerated octreotide or lanreot...